T1	intervention 0 11	Rivaroxaban
T2	location 1296 1298	UK
T3	total-participants 1389 1391	88
T4	eligibility 1392 1436	treatment-na√Øve early breast cancer patients
T6	outcome-Measure 1711 1732	change in tumour Ki67
T7	outcome-Measure 1769 1916	tumour markers of apoptosis and angiogenesis, extrinsic clotting pathway activation and systemic markers of metastasis, tumour load and coagulation
T8	control 24 36	no treatment
T5	outcome 2030 2046	survival benefit
T9	outcome 2175 2201	potential survival benefit
